NEW YORK, April 11, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Eli Lilly & Co. (NYSE: LLY), UnitedHealth Group, Inc. (NYSE:
UNH), Valeant Pharmaceuticals International, Inc. (NYSE: VRX),
Forest Laboratories Inc. (NYSE: FRX), and Zoetis Inc. (NYSE: ZTS).
Private wealth members receive these notes ahead of publication. To
reserve complementary membership, limited openings are available
at: http://www.AnalystsReview.com/register
--
Eli Lilly & Co. Analyst Notes
On March 31, 2014, Eli Lilly &
Co. (Lilly) announced that the U.S. District Court for the Southern
District of Indiana has ruled in
the Company's favor regarding the vitamin dosage regimen patent for
Alimta® (pemetrexed for injection). According to the
Company, in the case of Eli Lilly and Company v. Teva Parenteral
Medicines Inc., et al., the court ruled the vitamin dosage
regimen patent is valid and enforceable. Additionally, the Company
stated that the patent provides intellectual property protection
for Alimta until 2022. Michael J.
Harrington, Senior Vice President and General Counsel for
Lilly, remarked, "We are pleased with the District Court's ruling
on Alimta's vitamin dosage regimen patent and are confident that
the patent is valid and enforceable. The significant scientific
research that Lilly performed in support of the vitamin dosage
regimen patent deserves intellectual property protection. We
continue to emphasize that protection of intellectual property
rights is extremely important to the biopharmaceutical industry and
the patients we serve." The full analyst notes on Eli Lilly &
Co. are available to download free of charge at:
http://www.AnalystsReview.com/04112014/LLY/report.pdf
--
UnitedHealth Group, Inc. Analyst Notes
On March 27, 2014, UnitedHealth
Group, Inc. (UnitedHealth Group) announced that the UnitedHealth
Group Center for Nursing Advancement (CFNA) reported the formation
of an External Nurse Advisory Board (ENAB). According to
UnitedHealth, the goal of the ENAB is to inform, create and evolve
nursing best practices in order to create strong partnerships
across nursing, education and the health care industry influence
nursing policy and changes in the national landscape; and further
the nursing profession. Commenting on the development, Jeannine Rivet, Executive Vice President,
UnitedHealth Group and Executive Sponsor of the CFNA, stated, "The
Center for Nursing Advancement (CFNA) was founded in 2008 to
prepare nurses for expanding roles and solving the most pressing
health care problems of today and tomorrow, tackling the challenges
of a health care system in transition and shaping the future of the
health care industry. The ENAB was created to further this mission,
not only for the more than 24,000 UnitedHealth Group nurse
employees in the United States and
seven other countries, but for nurses everywhere." The full analyst
notes on UnitedHealth Group, Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/04112014/UNH/report.pdf
--
Valeant Pharmaceuticals International, Inc. Analyst
Notes
On March 25, 2014, Valeant
Pharmaceuticals International, Inc. (Valeant) and Actavis plc
(Actavis) announced that the U.S. Food and Drug Administration
(FDA) has approved the New Drug Application (NDA) for Metronidazole
1.3% Vaginal Gel, an antibiotic for the treatment of bacterial
vaginosis (BV). According to the Company, Actavis acquired the
rights to Metronidazole 1.3% from Valeant Pharmaceuticals
International in April 2013 and under
the terms of the agreement with Valeant, Actavis will acquire the
rights to Metronidazole 1.3% for up to $57
million in upfront payments, milestone payments and certain
guaranteed royalty payments during the first three years of
commercialization depending on market conditions. The Company
further stated that Actavis will also pay ongoing royalties to
Valeant after the first three years of commercialization. The full
analyst notes on Valeant Pharmaceuticals International, Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/04112014/VRX/report.pdf
--
Forest Laboratories Inc. Analyst Notes
On March 31, 2014, Forest
Laboratories Inc. (Forest Laboratories), together with Gedeon
Richter Plc., reported positive topline results from a Phase IIb
trial evaluating the efficacy and safety of the investigational
antipsychotic cariprazine in patients with bipolar depression.
According to the Company, the trial consisted of four treatment
groups: cariprazine 0.75 mg/day, 1.5 mg/day, 3.0 mg/day, and
placebo. Commenting on the results, Marco
Taglietti, M.D., Executive Vice President of Drug
Development and Research at Forest Laboratories, stated, "We are
pleased with the positive results of this study. In addition to
previously completed Phase III trials in schizophrenia and bipolar
mania, we now have positive Phase IIb studies for cariprazine in
both bipolar depression and major depressive disorder. Our goal is
to continue developing cariprazine for patients with a broad range
of psychiatric conditions." The full analyst notes on Forest
Laboratories Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04112014/FRX/report.pdf
--
Zoetis Inc. Analyst Notes
On March 31, 2014, Zoetis Inc.
(Zoetis) announced that it will host a webcast and conference call
at 8:30 a.m. EDT on May 6, 2014. According to Zoetis, CEO Juan Ramón
Alaix and Executive Vice President and CFO Rick Passov will review Q1 2014 financial
results and respond to questions from financial analysts during the
call. Additionally, the Company stated that a replay of the webcast
will be archived and made available on the same day. The full
analyst notes on Zoetis Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/04112014/ZTS/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://AnalystsReview.com
SOURCE Analysts Review